Sarah Gilbert’s chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She leads the Jenner Institute programme in influenza vaccine development and now also works on vaccines for many different emerging pathogens. Working with colleagues in the Jenner Institute research labs, the Clinical Biomanufacturing Facility and Centre for Clinical Vaccinology and Tropical Medicine, all situated on the Old Road Campus in Oxford, she is able to take novel vaccines from design to clinical development, with a particular interest in the rapid transfer of vaccines into GMP manufacturing and first in human trials.
Additionally she collaborates on the development of many veterinary vaccines including influenza in pigs and chickens, Rift Valley Fever virus, African Horse Sickness virus, Bluetongue Virus and MERS, with colleagues at the Pirbright Institute and elsewhere. She is the co-founder of the Oxford spinout company Vaccitech which is now running phase II trials of viral vectored vaccines initially developed at Oxford University.